Tuesday, January 04, 2022 2:03:16 PM
After the split:
"Reddington will purchase an additional tranche of shares of common stock from the Company such that after the issuance thereof Reddington shall own 90% of the total issued and outstanding shares of the Company’s common stock"
https://www.otcmarkets.com/filing/html?id=15285364&guid=RfSwkHUxZWc5Oth
Reddington owns about 42% pre split, 21,136,250
https://www.otcmarkets.com/filing/html?id=15285471&guid=RfSwkHUxZWc5Oth
Current share structure
Authorized Shares 50,000,000 01/03/2022
Outstanding Shares 49,398,621 01/03/2022
Post split share structure will be
Authorized Shares 50,000,000
Outstanding Shares 989,972
Reddington post split shares will be 422,725 so Reddington will have to purchase a lot of shares to get to 90%.
"Reddington will purchase an additional tranche of shares of common stock from the Company such that after the issuance thereof Reddington shall own 90% of the total issued and outstanding shares of the Company’s common stock"
https://www.otcmarkets.com/filing/html?id=15285364&guid=RfSwkHUxZWc5Oth
Reddington owns about 42% pre split, 21,136,250
https://www.otcmarkets.com/filing/html?id=15285471&guid=RfSwkHUxZWc5Oth
Current share structure
Authorized Shares 50,000,000 01/03/2022
Outstanding Shares 49,398,621 01/03/2022
Post split share structure will be
Authorized Shares 50,000,000
Outstanding Shares 989,972
Reddington post split shares will be 422,725 so Reddington will have to purchase a lot of shares to get to 90%.
Recent NORD News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2026 07:42:23 PM
- Nordicus Partners Corporation Corporate Update • GlobeNewswire Inc. • 02/06/2026 04:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 06:28:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 08:30:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 02:00:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 06:08:32 PM
- NoviThera has initiated the first efficacy animal studies • GlobeNewswire Inc. • 11/13/2025 04:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/28/2025 08:05:16 PM
- Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats. • GlobeNewswire Inc. • 10/22/2025 01:00:00 PM
- Orocidin develops novel cGMP manufacturing process in collaboration with Syngene • GlobeNewswire Inc. • 10/20/2025 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/14/2025 01:00:24 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 10/14/2025 01:00:23 PM
- Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApS • GlobeNewswire Inc. • 10/03/2025 08:38:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/30/2025 01:43:00 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2025 10:07:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2025 06:45:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2025 01:38:25 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/05/2025 06:43:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/29/2025 07:21:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2025 12:01:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/01/2025 07:55:13 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 06/27/2025 01:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2025 01:00:36 PM

